Wade Lange

Prof. Ehrlich, we found the targets for your magic bullets! We updated our video from three years ago and posted it on our new website, https://www.fbbbio.com. #venturecapital #angelinvestor #cancer #hivaids #bioOS #biotechnology #diagnostics #innovation #technology #management #startups #liquidbiopsy #neurodegenerativediseases #multiplesclerosis #parkinsonsdisease #alzheimersdisease #longhaulers #longcovid #humangenome #onetestonelife #longevity #artificialintelligence #rna #rnaseq #personalizedprevention OK

16

2 Comments

CancerCell www.cancercellinc.com a Leonhardt Ventures startup focused on bioelectric treatment of cancer with 13 issued patents and more pending. 1. Jam communication of cancer cells. 2. Reprogram surface proteins and electrical charge to illicit and immune response. 3. Starve tumor of blood supply. 4. Program apoptosis of cancer cells. 5. Suppress cancer tumor growth with klotho expression. 6. Improve gut microbiota and immune system to fight back against cancer. 7. Reduce chronic inflammation.

2

2 Comments

Using 'representation vectors' instead of prompt engineering to modulate #LLM responses enables tuneable behavior: https://lnkd.in/eUwSUvtg

10

1 Comment

It's been 288 years since Benjamin Franklin first advised that "An ounce of prevention is worth of pound" of cure". Glad to see bipartisan efforts of the US Congress to apply that concept to how we assess #healthcare spending via the "Prevention Health Savings Act": https://lnkd.in/g492Xmni Past article: https://lnkd.in/g4_AWPyN The Alliance for Regenerative Medicine correctly points out that this same thinking should be applied to how we assess the medical and economic value of potential #genetherapy #geneediting #celltherapy #cures that may have a high one-time up-front cost, but that offer a potential lifetime of benefit AND that might also add to the economic productivity of patients (and caregivers) whose lives have been transformed by such therapies. #healthcarepolicy

12

Also in This Issue: The single-drop pan-diagnostic is back (for real this time) Early Cancer Detection tests - ready for prime time? Adding liquid bx to standard tumor staging acronym Bird flu update #sensitiveandspecific #diagnostics #genetics #genomics #personalizedmedicine #infraredspectroscopy #proteomics #biomarkers #diseasedetection #birdflu #H5N1 #MCED #MCEDtest #earlydetection #liquidbiopsy #olympics #wastewatersurveillance

18

A must read for those interested in understanding the landscape of companies seeking to deliver innovative ways of treating type 1 diabetes - and in Sernova's case, providing a 'functional cure' to T1D patients. Chris Sandburg from Insider Financial describes Sernova as: 'The best of breed in T1D....with the only proven vascularized device in clinical trials and the ability to scale their payload size with larger pouches. They currently have a $70 million market cap. The exit for SEOVF is a buyout over the $2.9 billion that SNY paid for an inferior asset. If there is no buyout, they will be able to license to a number of pharmas looking for an approved delivery vehicle for their stem cell lines as well as use of EVO’s stem cell derived islets. We see the big pharmas such as AZN, SNY, NVO are circling SEOVF as the company progresses. T1D is a huge market and buying best of breed in biotech can be a rewarding strategy. #T1D #CellTherapy #iPSC #Biotech

35

Epoch 19: The AutoImmune Renaissance A few weeks back we went into detail on this topic, with a primary focus on CAR-T. Today we broaden to cover additional modalities. 👉CD19 👉CAR-T 👉FcRN 👉T-Cell Engagers https://lnkd.in/dEkBy2bY

1

Amplifying this excellent analysis about "biotech behemoths" of the last 15 years shared by Eddie Eltoukhy from Pear VC. 👇 💡 One thing that jumps out at me from this analysis is the value of being among the crop of sentinel companies in an exciting new category. Within the #cardiology space ... MyoKardia gets a lot of R&D credit and landed a huge M&A premium for being among the first to pioneer precisions medicines the #cardiomyopathy field (even though in hindsight most would agree Bristol Myers Squibb overpaid). The acquisition of Carmot Therapeutics, Inc. by Roche would have also made this list but they were founded 1 year before the analysis cutoff. I agree with Eddie that there are likely some future "behemoths" lurking in the #cardiometabolic space -- including, hopefully Tenaya Therapeutics! -- but it will be harder to break through the noise. Within the #AAV #genetherapy space, AveXis, Spark Therapeutics, Inc., and Audentes make the "behemoth" cut as they were acquired by Big Pharma during a time when there was a lot of excitement about that modality. There are AAV companies today that arguably have more robust and exciting clinical data and technology platforms than Spark and Audentes ever had, but valuations have subsequently plummeted and they will likely never make the "biotech behemoth" list (and in hindsight most would say that Roche and Astellas Pharma overpaid. Within the #geneediting space ... it is remarkable how a technology that was first published on in 2012 has already spawned two "biotech behemoths" in Intellia Therapeutics, Inc. and CRISPR Therapeutics that have both generated incredible clinical data. That shows how rapidly we can now translate new scientific insights into human therapeutics. However, most would agree that it may be harder for new "behemoths" to emerge from among the long tail of gene editing companies that have subsequently emerged, even though their editing technologies may be superior to the original CRISPR/Cas9. 💡 However ... not all sentinels become "behemoths", and why some succeed and some do not is worthy of its own analysis: - In the cell therapy space, bluebird bio was a sentinel pioneer that came down to earth despite great investors and leaders and 4 approved products that have objectively saved lives. - In the AAV space, REGENXBIO Inc. was a sentinel pioneer that spawned two "behemoths" (AveXis and Audentes) but has not yet become one, despite also having generated exciting clinical data of its own. - In the editing space, Sangamo Therapeutics, Inc. was a sentinel pioneer that did not enjoy the success of [Side note: The one thing I don't love methodologically is the choice of using market value at IPO OR as of 12/31/23. Many companies had artificially frothy valuations in the 2019-2021 period, and those prices came down to the earth by now. Sana Biotechnology, Inc. is one example ... they would not make the "behemoth" cut based on stock price on 12/31/23.]

15

1 Comment

Wondering how you will navigate the new FDA stance on LDTs? We are here to discuss strategies and paths to success. Contact i5 BioPartners to learn more.

11

1 Comment

If you're looking to expand your knowledge on working with FFPE tissue for #nucleicacid analysis check out "Successfully Overcoming the Challenges of Working with FFPE Samples," where @martyenseberger from Promega Corporation expertly summarizes the best practices for working with FFPE. #genomic #transcriptomic #FFPE

20

End of last year, Flagship Pioneering told to raise $3 B… Then they raised $3.6 B.. with $2.6 B for biotech venture building, and $ 1 B tagged for M&A / strategic partnerships. That’s a plan.. and the way to go! #bravo #biotech #lifescience #recovery #investing #venturebuilding #leadership

21

1 Comment

Excellent way to spend 1 minute, 30 seconds. DSO shares via an embedded video in the article below how Modality.AI is making an impact with patients. It is wonderful to have NIH SEED as a partner on this journey. Relentless Venture Fund David "DSO" Suendermann-Oeft #Neurotech #AI #BIO2024 #precisionmedicine #clinicaltrials #healthtech #healthcare #digitalhealth

2

Our recent projects represent a good cross-section of the services we provide at Nucleus Automation Partners – 𝐬𝐜𝐫𝐢𝐩𝐭𝐢𝐧𝐠 for liquid handling instruments, custom code development for 𝐚𝐮𝐭𝐨𝐦𝐚𝐭𝐞𝐝 𝐝𝐚𝐭𝐚 𝐡𝐚𝐧𝐝𝐥𝐢𝐧𝐠, 𝐩𝐫𝐞-𝐩𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐚𝐮𝐭𝐨𝐦𝐚𝐭𝐢𝐨𝐧 𝐩𝐥𝐚𝐧𝐧𝐢𝐧𝐠, and 𝐭𝐫𝐚𝐢𝐧𝐢𝐧𝐠. Last week, we worked with two different public health labs in different regions of the country on 𝐍𝐆𝐒 workflows. One lab was seeing 𝐢𝐧𝐜𝐨𝐧𝐬𝐢𝐬𝐭𝐞𝐧𝐭 𝐩𝐢𝐩𝐞𝐭𝐭𝐢𝐧𝐠 𝐚𝐭 𝐥𝐨𝐰𝐞𝐫 𝐯𝐨𝐥𝐮𝐦𝐞𝐬. We identified the root cause and adjusted several liquid classes to significantly improve the results. They also desired greater 𝐭𝐫𝐚𝐧𝐬𝐩𝐚𝐫𝐞𝐧𝐜𝐲 in their quant & norm process, and we set them up with code specific to their process that allows 𝐭𝐨𝐭𝐚𝐥 𝐟𝐥𝐞𝐱𝐢𝐛𝐢𝐥𝐢𝐭𝐲 on how to handle edge cases, and 𝐯𝐢𝐬𝐢𝐛𝐢𝐥𝐢𝐭𝐲 as to how the calculations are being made. We incorporated a workflow previously handled with an internal spreadsheet into the automated code. The other lab was seeking to make some custom modifications to their script, and had a number of 𝐬𝐦𝐚𝐥𝐥 𝐚𝐝𝐣𝐮𝐬𝐭𝐦𝐞𝐧𝐭𝐬 needed in the way their robot was taught – a series of small, individually relatively minor issues but when stacked up presented troublesome problems during longer runs. In one case it was consistently transporting the lid when it should have been transporting the lid + plate together, which clearly leads to downstream problems! In addition to find-tuning these aspects, we adjusted the worktable to better fit the needs of their application. This week, we are heading to the Carolinas. As part of our 𝐚𝐮𝐭𝐨𝐦𝐚𝐭𝐢𝐨𝐧 𝐩𝐥𝐚𝐧𝐧𝐢𝐧𝐠 𝐬𝐞𝐫𝐯𝐢𝐜𝐞𝐬, we previously helped this customer identify options for 𝐜𝐨𝐥𝐨𝐧𝐲 𝐩𝐢𝐜𝐤𝐢𝐧𝐠. With the hardware ordered and now on-site, we will get this application setup for them and train their team. And since they work with a number of different liquid handling platforms, we are able to take care of several other automation projects during our visit as well, 𝒏𝒐𝒕 𝒐𝒏𝒍𝒚 𝒔𝒂𝒗𝒊𝒏𝒈 𝒕𝒉𝒆𝒎 𝒕𝒊𝒎𝒆 𝒃𝒖𝒕 𝒔𝒂𝒗𝒊𝒏𝒈 𝒐𝒏 𝒕𝒓𝒂𝒗𝒆𝒍 𝒆𝒙𝒑𝒆𝒏𝒔𝒆. If your liquid handler isn’t doing exactly what you want it to do, reach out to us and we’ll get you taken care of. Nucleus Automation Partners Mike Mueller Kelly Tracy #labautomation #liquidhandling #ngs #colonypicking #biopharma #publichealth

16

Unlocking the full potential of gene therapy requires a vector that goes beyond limits. Enter BioViva's CMV gene delivery system: its large capacity allows for precise control, efficient delivery, while making gene therapy more cost-effective. It's not just about extending lives, it's about transforming healthcare. https://lnkd.in/gNNWeg7F #bioviva #genetherapy #lizparrish #biohacking #biohacker #CRISPR #biohack #fitness #healthylifestyle #motivation #keto #nootropics #nutrition #biohackers #biohackingsecrets #longevity #meditation #brainhealth #mindfulness #healthy #functionalmedicine #antiaging #heart disease #telomeres #klotho #healthnews #dementia #alzheimers

36

1 Comment

Important work by the FDA featuring the GlycoStation, a high-sensitivity lectin array scanner manufactured by Mx (Mx is pronounced emukk www.emukk.com). The custom-designed array features nine selected lectins providing critical insights into glycosylation of therapeutic antibodies. A tailored lectin microarray for rapid glycan profiling of therapeutic monoclonal antibodies Shen Luo and Baolin Zhang Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA "Abstract: Glycosylation plays a crucial role in determining the quality and efficacy of therapeutic antibodies. This necessitates a thorough analysis and monitoring process to ensure consistent product quality during manufacturing. In this study, we introduce a custom-designed lectin microarray featuring nine distinct lectins: rPhoSL, rOTH3, RCA120, rMan2, MAL_I, rPSL1a, PHAE, rMOA, and PHAL. These lectins have been specifically tailored to selectively bind to common N-glycan epitopes found in therapeutic IgG antibodies. By utilizing intact glycoprotein samples, our nine-lectin microarray provides a high-throughput platform for rapid glycan profiling, enabling comparative analysis of glycosylation patterns. Our results demonstrate the practical utility of this microarray in assessing glycosylation across various manufacturing batches or between biosimilar and innovator products. This capacity empowers informed decision- making in the development and production of therapeutic antibodies." https://lnkd.in/gG3b6hWV

8

3 Comments

ℹ️ Insightful Reuters article delving into the current landscape of CAR-T treatments in the U.S. These therapies offer hope to patients for whom standard treatments have proven ineffective. Time is of the essence for these individuals, and manufacturers are ramping up efforts to boost production efficiency by leveraging semi-automation and pre-engineered cells. 🚀 🔮 The future of CAR-T therapy lies in seamless integration of these advancements. Key players in the U.S. and Europe are poised to revolutionize treatment accessibility through closed and fully automated cell therapy production platforms. This innovation promises to bring CAR-T therapy directly to patients' doorsteps, fostering a new era of collaboration with treating hospitals. 🏥 #CAR-T #CellTherapy #HealthcareInnovation #TreatmentDevelopment

19

Is there an invert relation between federal interest rates and number of biotech IPOs? The answer, based on the last 5 years of data, is yes. However, if you expand the data to 10 years, you see that number of IPOs continues to grow until the interest rate reaches 2.5%. Will we need to get back to those levels before seeing greater activity? KYBORA can help you navigate these turbulent times. Please reach out. #biotech #IPO #interestrates #biopharma #fundraising

22

Our upcoming "office hours" session on August 20th is a great, informal way to have your questions on DILIsym and RENAsym (liver and kidney safety prediction platforms) addressed! Please join us by registering and submitting insightful questions! #SimulationsPlus #DILIsym #QSP

17